Exenatide shows modest effect for obesity in adolescents

  • Weghuber D & al.
  • Pediatr Obes
  • 16 Feb 2020

  • curated by Emily Willingham, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Exenatide for adolescents with severe obesity yielded modest reductions in BMI and improvements in cholesterol levels and glucose tolerance in this randomized controlled trial.

Why this matters

  • Pharmacological therapies for this population are limited.

Key results

  • Compared with placebo, the exenatide group experienced reductions in (95% CIs):
    • BMI: −0.83 kg/m2 (−1.68 to 0.01 kg/m2; P<.05>
    • Percentage at BMI 95% percentile: −2.9% (−5.4% to −0.3%).
    • Weight: −3.0 kg (−5.8 to −0.1 kg).
    • Waist circumference: −3.2 cm (−5.8 to −0.7 cm).
    • Subcutaneous adipose tissue: −552 cm3 (−989 to −114 cm3).
    • 2-hour glucose during oral glucose tolerance test: −15.3 mg/dL (−27.5 to −3.1 mg/dL).
    • Low-density lipoprotein cholesterol: −7.3 mg/dL (−14.2 to −0.4 mg/dL).
  • Safety and tolerability were similar to placebo, with more mild adverse events with exenatide and similar discontinuation rates.

Study design

  • Double-blind, placebo-controlled trial of 44 patients, ages 10-18 years randomly allocated to exenatide extended release (2 mg; n=22) or placebo (n=22) weekly subcutaneous injections.
  • Funding: European Union Seventh Framework Programme; Regional Research Council in Uppsala‐Örebro, Sweden; others.

Limitations

  • Small numbers, trial duration of 6 months.